
Diaceutics, registered in Northern Ireland as NI055207, provides diagnostic intelligence and engagement to biopharma teams.
diaceutics.comCrawled Nov 10, 2026
Diagnostic-driven therapies are changing what’s possible for patients. But the commercial model has not kept pace.
At Fierce Pharma Week 2026, industry leaders explored how commercial teams can identify the signals that matter, turn insight into action and coordinate engagement around the customer journey.
Precision Medicine Educators help labs adopt new tests, improve biomarker testing and advance precision medicine through expert scientific engagement.
Diaceutics products turn diagnostic activity into earlier insight, targeted engagement and therapy adoption through Intelligence and Engagement Solutions.
Sarah Heming leads strategic marketing at Diaceutics, driving brand strategy and global marketing to enhance patient access to diagnostic-driven therapies in the pharma and biotech sectors.
Scott Phillips drives Diaceutics' Real World Data unit, focusing on partnerships, product innovation, and AI integration to enhance real-world evidence for the pharmaceutical industry.
Gosia Leitch leads Engagement Solutions, driving data-driven HCP strategies that enhance treatment adoption and optimize genomics utilization for global pharma partners.
D-Cubed Pharma uses real-world data to improve physician engagement and speed up therapy adoption for better patient outcomes.
Turn Diagnostic Intelligence Into Clearer Strategy and Stronger Diagnostic Readiness
Diaceutics launches its real-time Test Signal service in the US, enabling quicker identification of patients eligible for targeted therapies and enhancing precision medicine.
Discover Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces its unaudited interim results for the six months ended 30 June 2021
Discover Diaceutics PLC Annual Report 2020
Diaceutics fosters a flexible, people-focused culture to advance innovation in precision medicine.
Diaceutics offers career opportunities in healthcare challenges solved through science, data, technology, and innovation.
Join Diaceutics and build a career in precision medicine. Where innovation, diagnostics and technology come together to improve patient outcomes.
Ken Ruppel, VP at Diaceutics, leads efforts to align diagnostic strategies with therapeutic launches, enhancing patient access to precision medicine through expert-led education and flawless execution.
Diaceutics unlocks the potential of diagnostic-driven therapies with intelligence, data and expert engagement to connect more patients to treatment.
Diaceutics outlines its corporate governance, board responsibilities, and commitment to transparency and accountability.
Download Diaceutics' Corporate Overview Presentation.
Access the report to find out more about Diaceutics Corporate Overview Presentation, Dec 2025
Diaceutics provides contact options for sales, investor, and career inquiries, including collaboration and investment opportunities.
Diaceutics speeds up precision medicine commercialization using diagnostic intelligence and healthcare professional engagement.
Unless otherwise stated, any defined terms in here shall have the meaning set out in the DXRX Membership Terms.
Volunteer Expert Advisor Terms (Event Participation) - Download PDF
TPA's will be charged in accordance with the below table.
Precision for All, a UK-based initiative, aims to bridge gaps in biopharma innovation by leveraging AI and generative tools like Midjourney. The project focuses on accelerating drug discovery and development by making advanced technologies accessible to smaller teams and researchers. It highlights the role of generative AI in streamlining workflows and reducing barriers to entry in precision medicine.
Oct 2026BioPharma DiveNews article
Diaceutics reports rising recurring revenue, a stronger order book, and positive free cash flow in mid-2026. The company expands its partnership with US biopharma firm Syndax Pharmaceuticals, fueling momentum in precision medicine. These developments align with increased demand for its specialized solutions.
Sep 2026Yahoo FinanceNews article
Diaceutics introduces the *Precision for All* initiative, a strategic collaboration platform uniting senior leaders from the biopharmaceutical sector. The event launches during Fierce Pharma Week 2026, aiming to foster industry-wide engagement and knowledge exchange. The company positions itself as a bridge for cross-sector dialogue in precision medicine.
Sep 2026News-MedicalNews article
Diaceutics and the Precision Cancer Consortium (PCC) are launching a study to evaluate the consistency of genetic variant detection across different next-generation sequencing (NGS) panels and platforms used in clinical settings. The initiative aims to improve precision oncology by supporting more accurate biomarker testing for cancer patients. The collaboration seeks to address variability in sequencing results, which can impact treatment decisions.
Aug 2026Precision Cancer ConsortiumNews article